A test kit for detecting viral or biochemical infections is disclosed comprising a housing, at least one test well in the housing comprising a test material for detecting and indicating the presence of a virus, biochemical agent or antibodies in a test sample, and a control material adjacent the housing comprising a damage indicating material, a taggant material or a track and trace element. A method of detecting viral or biochemical infections using the test kit is also disclosed. The method includes contacting a test material with a test sample, and observing any change in appearance of the test material to determine the presence or absence of the virus, biochemical agent or antibodies.

A system and method for detecting pathogenetic analytes including exciting a large target input area with radiation to produce scattered light to form an input beam, reformatting, with an optical slicer system, the input beam to produce an output beam, dispersing the output beam to produce an output area, capturing excitation data from the output area; and determining, with a processor, a presence of a particular analyte in the input area based on the excitation data. The input area can be greater than 100 micron squared and less than one million microns squared. The optical slicer system can be a high throughput virtual slit system. SERS analysis detects analytes of interest with both high resolution and sensitivity simultaneously, and is applicable for detection of the presence of viruses.

The present disclosure relates to apparatuses and methods for detecting the amount and/or type of one or more analytes-of-interests such as biomarkers in a sample. In embodiments, the disclosure includes a method for determining a humoral response due to the presence of a target infectious agent or vaccine. In embodiments, detecting emission light from one or more fluorescent complexes is used to determine a type and/or quantity of the plurality of biomarkers.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the strain of coronavirus that causes coronavirus disease 2019 (COVID-19), the respiratory illness responsible for the COVID-19 pandemic. Antibodies produced from an immune response against SARS-CoV-2 infection are used to analyze prior exposure to the virus. The present invention provides methods for detecting antibodies in response to SARS-CoV-2 infection in a single multiplex immunoassay.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the strain of coronavirus that causes coronavirus disease 2019 (COVID-19), the respiratory illness responsible for the COVID-19 pandemic. Antibodies produced from an immune response against SARS-CoV-2 infection are used to analyze prior exposure to the virus. The present invention provides methods for detecting antibodies in response to SARS-CoV-2 infection in a single multiplex immunoassay.

A platform for sampling viral particles on surfaces and porous structures and in the air. The sampling platform includes, for example, a collection pad configured for quantitating viral loads in a fomite or captured form the air. A reservoir or liquid container is associated with the collection pad for interacting a virus collection zone of the collection pad. A liquid medium is disposed within the container. At least one pump is operably configured to move the liquid medium or air through the collection pad for extracting viral particles from the environment.

Early stage, rapid, low-cost detection of disease components in a biological sample is critically important. A point of care device can include a collection region and can be used to hold a sample that is combined with a fluorescent dye and a plurality of magnetic particles such that disease components in the sample are tagged with the fluorescent dye and the plurality of magnetic particles. At least one magnet can be located next to the collection region to establish a magnetic field gradient to draw the tagged disease components into the collection region from the device. A fluorescence microscope can image the small collection region based on the fluorescent dye to detect the disease components. The fluorescence microscope uses light to excite the fluorescent dye and a filter to transmit light emitted by the fluorescent dye to the fluorescence microscope, while restricting light used to excite the fluorescent dye.

A method for pooled sample testing for a target substance using compressed sensing includes receiving a plurality of individual samples, determining a mixing matrix for a plurality of pooled sample mixtures to create by mixing portions of selected ones of the plurality of individual samples, and determining an allocation matrix for the plurality of pooled samples, wherein the allocation matrix allocations portions of each of the plurality of pooled samples for each test, performing mixing to create the plurality of pooled sample mixtures based on the mixing matrix and the allocation matrix, performing quantitative tests on the plurality of pooled sample mixtures so as to estimate an amount of the target substance contained within each of the plurality of pooled sample mixtures, and decoding results of the quantitative tests to determine quantitative estimates of amount of the target substance in each of the plurality of individual samples.

The disclosure is directed to methods and kits for detecting neutralizing antibodies against a coronavirus (e.g., SARS-CoV-2) in a sample, such as a plasma sample or pooled plasma composition. The methods utilize a panel of SARS-CoV-2 neutralizing antibodies as a positive control. The kit may be a rapid detection kit that measures neutralizing antibodies using the provided methods.

Quantum dots conjugated to SARS-CoV-2 Spike protein receptor binding domain (RBD) interact with gold nanoparticles bound to angiotensin converting enzyme 2 (ACE2) and thus undergo energy transfer. This energy transfer indicates RBD/ACE binding and can be used to assay for inhibitors thereof. Moreover, these labeled quantum dots were found to undergo endocytosis in cells expressing ACE2.